0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Efectos hemodinámicos beneficiosos y sostenidos del prazosin en la insuficiencia cardiaca

      , ,

      Cardiology

      S. Karger AG

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          En casi todos los enfermos estudiados por nuestro grupo se observo la respuesta maxima con 2 mg de prazosin cada 6 a 8 horas. Las investigaciones farmacocinéticas indican que esta es la dosis optima que puede utilizarse en cualquier programa terapéutico en la mayoría de pacientes. No surgió taquifilaxia a dosis seriadas en término de 24 horas en nuestro estudio. La administración de prazosin a largo plazo fue bien tolerada por los enfermos, y no hubo necesidad de suspender el uso del fármaco .en ningún momento. Los efectos benefíciosos inmediatos en el gasto cardiaco y la presión diastólica de arteria pulmonar persistieron después de tres meses de administrar el medicamento, y después de interrumpir su uso se apreció que, cuando se reemprendía, se obtuvieron esencialmente los mismos incrementos en el gasto y las mismas disminuciones en la presión diastólica de arteria pulmonar.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          978-3-8055-1557-3
          978-3-318-01519-5
          0008-6312
          1421-9751
          1980
          1980
          07 November 2008
          : 66
          : Suppl 2
          : 162-168
          Affiliations
          Escuela de Medicina, Stanford University, Stanford, California, E.U.A.
          Article
          173023 Cardiology 1980;66:162–168
          10.1159/000173023
          6456814
          © 1980 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Categories
          Prazosin en Enfermedad Cardiaca

          General medicine, Neurology, Cardiovascular Medicine, Internal medicine, Nephrology

          Comments

          Comment on this article